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The proliferative activity of breast cancer cells is widely regarded
as a very useful prognostic indicator. To date, numerous methods
have been employed to assess proliferative activity, including
counting mitotic figures (Meyer et al, 1986; Meyer, 1986;
McGurrin et al, 1987; Hall and Levison, 1990; Woosley, 1991;
Linden et al, 1992; Weidner et al, 1994; Collan et al, 1996), the
thymidine labelling index (TLI; Meyer, 1986; Kamel et al, 1989;
Silverstrini et al, 1997), the argyrophilic nucleolar organizer
region (AgNOR) (Raymond and Leong, 1989; Mourad et al, 1994)
and bromodeoxyuridine (BRDU; Lloveras et al, 1991; Weidner et
al, 1993). Counting mitotic figures in routinely stained paraffin
sections can give results comparable with more sophisticated
methods of determining proliferative activity when performed by
specially trained technicians (Weidner et al, 1994; Collan et al,
1996). The TLI method could provide prognostic information in
breast cancers in different stages (Silverstrini et al, 1997), but it
is a complex procedure requiring the use of radioisotopes. In
contrast, immunohistochemical evaluation of cell-associated anti-
gens requires neither expensive equipment nor special technical
skills. This method allows preservation of architectural and cyto-
logical information and has therefore been routinely applied to a
variety of tumours. The Ki-67 monoclonal antibody developed by
Gerdes et al (1983) is one of the most widely used proliferation-
associated markers. Recently, Cattoretti et al (1992) raised a novel
antibody, called MIB1, against recombinant parts of the Ki-67
antigen. They demonstrated that the MIB1 nuclear staining seen in
paraffin sections after microwave pretreatment essentially corre-
sponds to that of Ki-67 seen in frozen sections, and some breast
cancer studies have been conducted using this antibody
(Barbareschi et al, 1994; Keshgegian and Cnaan, 1995; Pinder et
al, 1995; Haerslev et al, 1996; Pietiläinen et al, 1996; Dettmar et
al, 1997). Most earlier studies have focused on invasive foci,
however, and few attempts have been made to assess the prolifera-
tive activity of malignant cells in intraductal components. As a
result, the relationships between the proliferative activity of malig-
nant cells in intraductal components and clinicopathological vari-
ables or clinical outcome have not yet been established. Recently,
the biological behaviour of intraductal components has been
receiving attention because extensive intraductal components have
been reported to show a significant association with local recur-
rence after breast-conserving therapy (Bartelink et al, 1988; Kurtz
et al, 1990). Moreover, early breast cancer in which intraductal
components predominate is increasingly being encountered in
clinical settings. In such cases, invasive foci are too small or the
cancer cells are too scarce for precise evaluation of proliferative
activity. In this regard, it is very important to evaluate the prolifer-
ative activity not only of invasive foci, but also of intraductal
components in invasive ductal breast carcinoma. This study was
designed to evaluate the proliferative activity of intraductal
components associated with invasive foci in early invasive ductal
breast carcinoma with predominantly intraductal components, and
to examine its relationship to the proliferative activity of invasive
foci. We also investigated whether the proliferative activity of
intraductal components had an impact on post-operative recur-
rence. Before beginning the study, we decided that if it was found
to have an impact we would investigate how it differed from the
impact of proliferative activity in the invasive foci.
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Summary The prognostic significance of the proliferative activities in intraductal components and invasive foci was investigated using 157
cases of invasive ductal breast carcinoma in which intraductal components predominated. Proliferative activity was expressed as the number
of MIB1-positive nuclei per 1000 cancer cells in the most active areas of intraductal components (MLI-DCIS) or invasive foci (MLI-INV). MLI-
DCIS correlated closely with MLI-INV (r = 0.710, 95% confidence interval, 0.623–0.780; P < 0.0001). Both MLI-DCIS and MLI-INV were
related to oestrogen receptor (ER) (P = 0.0006, P = 0.0028 respectively), grade of invasive tumour (P < 0.0001, P < 0.0001 respectively) and
classification of intraductal components (P < 0.0001, P < 0.0001 respectively). In the univariate disease-free survival analysis, both MLI-DCIS
and MLI-INV were found to be significant (P < 0.0001, P = 0.0003 respectively). However, in node-negative cases, only MLI-DCIS was
significant (P = 0.0416). Multivariate analysis revealed that MLI-DCIS was significant not only in all cases, but also in node-negative cases
(P = 0.0223,  P = 0.0426 respectively), whereas MLI-INV was not. These findings indicate that MIB1-determined proliferative activity of
intraductal components is a significant prognostic determinant of invasive ductal breast carcinoma in which intraductal components
predominate.
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MATERIALS AND METHODS
Patients
A total of 295 cases of UICC clinical stage I or II primary unilat-
eral invasive ductal breast carcinoma treated at Tokyo Women’s
Medical College Daini Hospital between 1987 and 1993 were
reviewed. To minimize the possible confounding effects of
potentially inadequate pathological examination, patients who had
undergone preoperative excisional biopsy, those for whom only a
small number of pathology slides (ten or less) were available or
those who had clinically multiple tumours were excluded. In addi-
tion, cases in which measurements of the specimen on histological
sections showed diameters of invasive foci of 21 mm or more and
cases in which the intraductal components were judged to be no
more than 25% of the entire tumour according to the surface area
ratio were excluded. The study population ultimately consisted of
157 patients. Patient and tumour characteristics are shown in Table
1. All patients were followed up for 49–128 months post-opera-
tively, and the median follow-up was 68 months.
The majority of node-positive patients received post-operative
adjuvant therapy consisting of combination chemotherapy with
cyclophosphamide, methotrexate and fluorouracil (CMF)
followed by oral fluorinated pyrimidine therapy. Usually, node-
negative patients did not receive chemotherapy. However, if a
patient was considered to be at high risk, oral fluorinated pyrimi-
dine therapy was given. If ER status was positive or unknown, the
patient also received tamoxifen therapy regardless of the type of
surgery or axillary lymph node status.
Among the mastectomy patients, 30 (26.8%) experienced local
recurrence and/or developed distant metastases, and 82 (73.2%)
have remained disease-free to date. Among the patients receiving
breast-conserving surgery, two (4.4%) experienced local recur-
rence, four (8.9%) developed distant metastases and 39 (86.7%)
have remained disease free to date.
Histological examination
After sampling for ER assay, the specimen was immediately fixed
in buffered 10% formalin and embedded in paraffin. Tumour size
was determined by direct measurement on histological sections.
The cases were divided into three groups according to the diameter
of the invasive focus: a pT1a group (≤ 5 mm), a pT1b group (> 5 to
10 mm) and a pT1c group (> 10 to 20 mm). In all cases, adequate
numbers of permanent paraffin sections (11–69, average 24.2)
were stained with haematoxylin and eosin (H&E). Every section
was evaluated by two of the authors (HI and MA) without knowl-
edge of either the immunohistochemical findings or the patient’s
clinical outcome.
Grading
All invasive ductal carcinomas were graded previously on a sepa-
rate occasion by two observers (HI and MA) using the method of
Bloom and Richardson as modified by Elston and Ellis (1991).
Intraductal components were classified by the same observers
according to the classification system of ductal carcinoma in situ
(DCIS; Holland et al, 1994).
Immunohistology
After histological examination, three representative blocks from
each patient were selected. All of the blocks selected were
confirmed to have intraductal components associated with inva-
sive foci. Proliferative activity was evaluated by using MIB1 anti-
body, as described previously (Imamura et al, 1997). After
deparaffinization and dehydration, the sections were placed in
0.01 M citrate buffer at pH 6.0 for antigen retrieval. Sections were
boiled five times at 95–100°C in 0.01 M citrate buffer for 3 min,
and allowed to cool at room temperature. After rinsing in phos-
phate-buffered saline, sections were incubated for 1 h at room
temperature with MIB1 antibody (Immunotech, Marseilles,
France) diluted at 1:100 and immunostained using the labelled
streptavidin biotin method. The complex was visualized with
diaminobenzidine, and the nuclei were lightly counterstained with
haematoxylin.
Table 1 Clinicopathological variables in 157 patients with invasive ductal
breast carcinoma
Variable Number of patients (%)
Age (years)
≤ 40 22 (14.0)
41–65 113 (72.0)
> 65 22 (14.0)
Tumour size
pT1a 9 (5.7)
pT1b 27 (17.2)
pT1c 121 (77.1)
Axillary lymph node status
Negative 84 (53.5)
Positive 73 (46.5)
Lymphatic vascular invasion
Negative 112 (71.3)
Positive 45 (28.7)
ERa
Negative 33 (21.0)
Positive 109 (69.4)
Unknown 15 (9.6)
Grade of invasive tumour
1 56 (35.7)
2 78 (49.6)
3 23 (14.7)
Classification of DCIS
Well differentiated 57 (36.3)
Moderately 69 (44.0)
Poorly 31 (19.7)
Type of surgery
Mastectomy 112 (71.3)
Wide excision 45 (28.7)
Adjuvant therapy
Yes 121 (77.1)
No 36 (22.9)
Recurrence
Yes 36 (22.9)
No 121 (77.1)
aThe ER determination was carried out by the EIA method with an assay kit
developed by Abbott Diagnostics (Chicago, IL, USA); 13 fmol mg–1 was taken
as the minimum value of ER positivity.174 H Imamura et al
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Cell counting
All fields of the sections were scanned at low (´40), medium (´100)
and high (´400) power. A cell was considered positive if any nuclear
staining was present. The five most strongly stained ducts were
selected from the intraductal components in each tissue section to
assess proliferative activity in the intraductal components.
Proliferative activity in the intraductal components was expressed as
the number of MIB1-positive nuclei per 1000 malignant cells viewed
in high-power fields of the five ducts (MIB1 labelling index in intra-
ductal components; MLI-DCIS). Briefly, colour photographs were
taken of the five ducts selected, and more than 1000 cancer cells were
counted on the photographs to calculate the number of MIB1-
positive cells. Neither necrotic areas nor the edges of the ducts were
included in the counting so as to minimize the possibility of immuno-
histochemical false positives. Likewise, proliferative activity in inva-
sive foci was expressed as the number of MIB1-positive nuclei per
1000 malignant cells viewed in high-power fields of the most
strongly stained portion of an invasive focus (MIB1 labelling index
in invasive foci; MLI-INV). Usually, five colour photographs were
taken of the most strongly stained portion of the invasive focus, but
more than six photographs were needed for scirrhous-type invasive
foci. Proliferative activity was jointly evaluated by two observers (HI
and MA) who had no information on the clinical outcome of the
patients.
Statistical analysis
The associations of MLI-DCIS and MLI-INV with various clinico-
pathological variables were evaluated by non-parametric tests: the
Mann–Whitney U-test for two categories, and the Kruskal–Wallis
test for three categories. We used linear regression, in which
measurements made by one observer (HI) were regressed against
or on to those made by another observer (MA), considered to
represent the standard. The correlation coefficient between MLI-
DCIS and MLI-INV was analysed by Spearman’s test on the log-
transformed data. A value of P < 0.05 was considered statistically
significant. Multivariate survival analysis using Cox’s propor-
tional hazard regression model was carried out to assess the inde-
pendent contribution of each variable to disease free-survival.
Overall survival was not analysed because of the small number of
disease-related deaths (ten patients died of recurrent breast
cancer). In this study, a computer program package (Stat View,
Abacus Concepts, Berkeley, CA, USA) was used for all statistical
testing and management of the database.
RESULTS
MLI-DCIS and MLI-INV in tumour specimens
Linear regression analysis revealed that the MLI-DCIS determined
by HI correlated significantly with the MLI-DCIS determined
by MA (r = 0.959; 95% confidence interval, 0.944–0.970;
P < 0.0001). Likewise, linear regression analysis revealed that the
MLI-INV determined by HI correlated significantly with the MLI-
INV determined by MA (r = 0.861, 95% confidence interval,
0.813–0.897; P < 0.0001). In each case, the higher of the two
independently determined MLI-DCIS and MLI-INV values,
considered to reflect tumour aggressiveness most accurately, was
adopted as the MLI-DCIS and MLI-INV.
Figure 1 shows the distribution of the MLI-DCIS and MLI-INV
values in the 157 breast cancers. The distribution was not normal,
and the median values for MLI-DCIS and MLI-INV were 91
(range 4–563) and 105 (range 8–587) respectively. As shown in
Figure 2, there was a highly positive correlation between log
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Figure 1 Distribution of MLI-DCIS and MLI-INV in 157 breast cancers. Arrows indicate the median value of 91 in MLI-DCIS and 105 in MLI-INV
Figure 2 Log-log plot of MLI-DCIS vs MLI-INV. The MLI-DCIS correlated
highly with the MLI-INV (r = 0.710, 95% confidence interval, 0.623–0.780;
P < 0.0001)
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MLI-DCIS and log MLI-INV (r = 0.710, 95% confidence interval,
0.623–0.780; P < 0.0001).
Associations of MLI-DCIS and MLI-INV with various
clinicopathological variables
MLI-DCIS correlated with three factors: ER status (P = 0.0006),
grade of invasive tumour (P < 0.0001) and DCIS classification
(P < 0.0001). MLI-DCIS did not correlate with age (P = 0.1794),
tumour size (P = 0.2514), axillary lymph node status (P = 0.1097),
peritumoral lymphatic vascular invasion (P = 0.2745), type of
surgery (P = 0.0712) or adjuvant therapy (P = 0.4688). MLI-
INV correlated with three factors: ER status (P = 0.0028),
grade of invasive tumour (P < 0.0001) and DCIS classification
(P < 0.0001). MLI-DCIS did not correlate with age (P = 0.064),
tumour size (P = 0.4154), axillary lymph node status (P = 0.0860),
peritumoral lymphatic vascular invasion (P = 0.9967), type of
surgery (P = 0.1512) or adjuvant therapy (P = 0.4119).
MLI-DCIS and MLI-INV in univariate analysis of survival
Univariate analysis focusing on disease-free survival revealed
axillary lymph node status (P = 0.0001), tumour size (P = 0.0019),
DCIS classification (P = 0.0093), grade of invasive tumour (P =
0.0005), MLI-DCIS (P < 0.0001) and MLI-INV (P = 0.0003) to be
significant prognostic factors. To assess the importance of various
risk factors in axillary lymph node status, univariate analysis was
conducted separately for the 84 node-negative cases and the 73
node-positive cases. In the node-negative cases, only MLI-DCIS
(P = 0.0416) remained an important variable predicting disease-
free survival. In the node-positive cases, DCIS classification (P =
0.0079), grade of invasive tumour (P < 0.0001), MLI-DCIS (P =
0.0004) and MLI-INV (P = 0.0003) remained the significant vari-
ables predicting disease-free survival (Table 2).
MLI-DCIS and MLI-INV in multivariate analysis of
survival
Following the univariate study, multivariate analysis was
conducted to test the independent prognostic value of these vari-
ables. We took into account that the number of events was rela-
tively few, and we selected the variables that were significant in
the univariate analysis. First, in order to assess the prognostic
Table 2 Univariate Cox analysis of disease-free survival
Disease-free survival
95% Cl RR P
All patients (n = 157)
Age 0.695–7.379 1.356 0.1404
Lymphatic vascular invasion 0.994–1.132 1.868 0.0636
Axillary lymph node status 0.096–0.464 3.878 0.0001
ER 0.353–1.850 0.504 0.6142
Tumour size 1.035–1.165 3.107 0.0019
DCIS classification 0.081–0.578 3.056 0.0093
Grade of invasive tumour 0.044–0.366 3.812 0.0005
MLI-DCIS 1.002–1.006 4.292 <0.0001
MLI-INV 1.002–1.006 3.648 0.0003
Type of surgery 0.914–1.032 0.951 0.3416
Adjuvant therapy 0.364–1.904 0.434 0.6646
Node-negative patients (n = 84)
Age 0.894–1.028 1.183 0.2370
Lymphatic vascular invasion 0.090–7.223 0.192 0.8479
ER 0.573–14.07 1.278 0.2013
Tumour size 0.974–1.342 1.641 0.1008
DCIS classification 0.100–3.586 0.561 0.7999
Grade of invasive tumour 0.060–7.331 0.334 0.7829
MLI-DCIS 1.000–1.008 2.038 0.0416
MLI-INV 0.995–1.007 0.253 0.8001
Type of surgery 0.109–2.677 0.754 0.4507
Adjuvant therapy 0.272–4.757 0.175 0.8607
Node-positive patients (n  = 73)
Age 0.538–6.000 1.634 0.1022
Lymphatic vascular invasion 0.233–1.253 1.435 0.1513
ER 0.503–2.827 0.399 0.6902
Tumour size 0.979–1.134 1.393 0.1637
DCIS classification 0.033–0.462 3.113 0.0079
Grade of invasive tumour 0.016–0.227 4.138 <0.0001
MLI-DCIS 1.002–1.008 3.565 0.0004
MLI-INV 1.003–1.009 3.659 0.0003
Type of surgery 0.137–1.503 1.294 0.1597
Adjuvant therapy 0.667–5.586 1.213 0.2252
RR, relative risk.
Table 3 Multivariate Cox analysis of disease-free survival (model 1)
Disease-free survival
95% Cl RR P
All patients (n = 157)
Axillary lymph node status 0.108–0.543 3.445 0.0006
MLI-DCIS 1.000–1.006 2.285 0.0223
DCIS classification 0.139–1.531 1.264 0.4057
Tumour size 0.973–1.120 1.186 0.2356
Node-negative patients (n = 84)
MLI-DCIS 1.000–1.017 2.027 0.0426
DCIS classification 0.286–581.7 1.317 0.4201
Tumour size 0.966–1.342 1.550 0.1212
Node-positive patients (n = 73)
MLI-DCIS 0.999–1.006 1.649 0.0991
DCIS classification 0.051–1.012 1.994 0.1391
Tumour size 0.941–1.112 0.537 0.5912
RR, relative risk.
Table 4 Multivariate Cox analysis of disease-free survival (model 2)
Disease-free survival
95% Cl RR P
All patients (n = 157)
Axillary lymph node status 0.101–0.502 3.640 0.0003
MLI-INV 0.999–1.005 1.418 0.1562
Grade of invasive tumour 0.049–0.529 3.007 0.0084
Tumour size 0.992–1.121 1.707 0.0878
Node-negative patients (n = 84)
MLI-INV 0.994–1.007 0.039 0.9691
Grade of invasive tumour 0.051–11.04 0.209 0.7992
Tumour size 0.972–1.352 1.621 0.1051
Node-positive patients (n = 73)
MLI-INV 0.999–1.007 1.693 0.0905
Grade of invasive tumour 0.024–0.457 2.998 0.0030
Tumour size 0.978–1.125 1.346 0.1784
RR, relative risk.176 H Imamura et al
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value of intraductal components on post-operative survival,
tumour size, axillary lymph node status, MLI-DCIS and DCIS
classification were entered into a multivariate analysis model
(model 1). The results showed that axillary lymph node status (P =
0.0006) and MLI-DCIS (P = 0.0223) were significant prognostic
factors predicting disease-free survival. To assess the importance
of variables as a risk factor for axillary lymph node status, multi-
variate analysis was conducted separately for the 84 node-negative
cases and the 73 node-positive cases. In the node-negative cases,
MLI-DCIS (P = 0.0426) remained an important variable
predicting disease-free survival. In the node-positive cases, no
factor remained an important variable predicting disease-free
survival (Table 3).
Second, in order to assess the prognostic value of invasive foci
on post-operative survival, tumour size, axillary lymph node
status, MLI-INV and grade of invasive tumour were entered into a
multivariate analysis model (model 2). The results showed that
axillary lymph node status (P = 0.0003) and grade of invasive
tumour (P = 0.0084) were significant prognostic factors predicting
disease-free survival. To assess the importance of variables as risk
factors in axillary lymph node status, multivariate analysis was
conducted separately for the 84 node-negative cases and the 73
node-positive cases. In the node-negative cases, no factor
remained an important variable predicting disease-free survival. In
the node-positive cases, only grade of invasive tumour (P =
0.0030) remained a significant variable predicting disease-free
survival (Table 4).
Multivariate analysis was also conducted in subgroups of
patients subdivided according to surgical treatment (mastectomy
vs breast-conserving surgery). The results were almost the same as
in the mastectomy group, and no significant factor was found in
the breast-conserving group (data not shown).
DISCUSSION
Various prognostic factors have been investigated in invasive
ductal breast carcinoma, and whereas many of the studies exam-
ined proliferative activity, most of them dealt with invasive foci
(Meyer et al, 1986; Meyer, 1986; McGurrin et al, 1987; Kamel et
al, 1989; Raymond and Leong, 1989; Hall and Levison, 1990;
Lloveras et al, 1991; Woosley, 1991; Linden et al, 1992; Weidner
et al, 1993; Mourad et al, 1994). This appears to have been because
the majority of invasive ductal breast carcinoma encountered clin-
ically in the past consisted predominantly of invasive foci and
because it was impossible to distinguish between invasive foci and
intraductal components by the assay methods available at the time.
Figure 3 Immunohistochemical features of MIB1 staining of an invasive ductal carcinoma from a 49-year-old woman. MLI-DCIS was calculated as 33 (left),
and MLI-INV was calculated as 155 (right), showing marked discrepancy between the two variables (original magnification ´ 400)However, as DCIS and invasive ductal breast carcinoma in which
the intraductal components predominate have become more
common in recent years, it has become increasingly important to
determine the significance of the cancer cell characteristics in the
intraductal components as prognostic factors. Furthermore, as a
result of advances in immunohistochemical methods, it is now
possible to assay the proliferative activity of invasive foci and
intraductal components separately. Clarifying the effect of the
proliferative activity of intraductal components on post-operative
survival is important in predicting the post-operative outcome of
early breast cancer in which the intraductal components predomi-
nate. At the same time, it would also appear to provide clinical
data that are useful for predicting the subsequent behaviour of
residual intraductal components following breast-conserving
therapy.
In the present study, there was a highly positive correlation
between MLI-DCIS and MLI-INV, and, using univariate analysis
of the entire group, we have also provided statistical evidence
that these two variables were significant prognostic variables.
However, whereas MLI-DCIS was a significant factor in the node-
negative group, MLI-INV was not. Multivariate analysis indicated
that MLI-DCIS is a significant prognostic determinant of disease-
free survival not only in the entire group but in the node-negative
group as well. Very recently, Dettmar et al (1997) studied the prog-
nostic significance of various factors, including MIB1 prolifera-
tion rate, in 90 node-negative cases. They found that MIB1
proliferation rate was a significant prognostic factor for disease-
free survival in the univariate analysis, but not in the multivariate
analysis. In their study, they did not restrict subject selection to
patients with DCIS-predominant breast cancer, and they did not
assay the proliferative activity of invasive foci and intraductal
components separately. These differences in patient selection and
methods of assaying MIB1 positivity may serve as an explanation
for the differences between our results and their results.
In our study, both the grade of the tumour and routine DCIS
classification failed to achieve significance in the node-negative
group. The grading system of Bloom and Richardson, as modified
by Elston and Ellis (1991), which is widely used in routine
pathology, only gives a rough estimate of the percentage of mitotic
cells. Likewise, the DCIS classification system by Holland et al
(1994) is convenient but overly simple, and subjective elements
cannot be eliminated. Therefore, the discrepancy between results
can be attributed to the varying character of these grading systems.
There are several possible reasons why MLI-INV was less
significant as a prognostic factor than MLI-DCIS. One is that the
fundamental biological behaviour threatening to predict recur-
rence of the tumour was not adequately reflected because the
invasive foci were so small in our series. Another possibility is
difficulty evaluating the proliferative activity of cancer cells in an
invasive focus itself. More specifically, the fact that it is often
difficult to differentiate between cancer cells and stromal cells
when making cell counts, especially in scirrhous-type breast
cancer, in which the cancer cell nests are small and the stromal
cells prominent, can be cited as a possible reason for inaccurate
evaluations. In contrast, differentiating cancer cells from stromal
cells in intraductal components is only very rarely a problem,
regardless of the subtype. There is also the advantage of it being
easier to obtain accurate cell counts, because cancer cells form
nests of fixed size and the cancer cells seldom overlap each other.
Actually, we found some cases to possess discrepancy between
MLI-DCIS and MLI-INV (Figure 3). As a result, linear correlation
analysis of MLI-DCIS and MLI-INV between the two observers in
the present study showed fairly high interobserver agreement, but
the fact that MLI-DCIS yielded a higher interobserver agreement
than MLI-INV (r = 0.959 vs r = 0.861) suggested an advantage of
MLI-DCIS as a marker.
The 157 patients who served as the subjects of this study were a
subset limited to 50% of the Stage I or II patients. However, when
examined retrospectively, many cases had indications for breast-
conserving therapy, and they are expected to increase in the future
as a result of advances in imaging diagnosis. Under these circum-
stances, we think that showing that proliferative activity in intra-
ductal components was significant as a prognostic factor deserves
attention. We think it will be worthwhile to evaluate the relation-
ship between the MIB1 labelling index and post-operative recur-
rence after breast-conserving therapy. However, in our study, the
number of local recurrences after breast-conserving therapy was
too small to allow determination of a meaningful correlation
between the MIB1 labelling index and disease-free survival. We
consider both the adequacy of excision and radiotherapy to have
contributed to the favourable local control rate achieved in our
patients who underwent breast-conserving therapy. There may be a
complex interplay between residual intraductal components and
local recurrence after breast-conserving therapy. Long-term
studies involving large numbers of patients are needed to deter-
mine whether the proliferative activity of malignant cells found in
intraductal components, as reflected by MIB1, correlate with local
recurrence and/or patient survival following breast-conserving
therapy.
The biological behaviour and clinical classification of DCIS
have been attracting interest in recent years in association with
advances in diagnostic imaging and increases in breast-conserving
therapy. However, there has not been much interest thus far in
evaluating DCIS behaviour in invasive ductal carcinoma as a prog-
nostic factor. Recently, Gupta et al (1997) tried analysing 300
cases of invasive ductal carcinoma associated with DCIS, and
stated that the morphological features of DCIS enable prediction
of the clinical outcome of the patients. Expressed another way, this
means that it is possible to predict the outcome of invasive ductal
carcinoma early, and this is an issue that should be examined
further in a larger series of cases.
In conclusion, MIB1-determined proliferative activity in intra-
ductal components and invasive foci correlate closely, and both are
predictive of disease-free survival. Furthermore, the results of
multivariate analysis comparing proliferative activity in intra-
ductal components and invasive foci showed the former to be the
more important predictor, regardless of nodal status. Therefore,
MIB1-determined proliferative activity in intraductal components
does not simply reflect that in invasive foci, but is actually superior
in terms of predicting clinical outcome of invasive ductal breast
carcinoma in which intraductal components predominate, and is
thus a useful tool.
REFERENCES
Barbareschi M, Girlando S, Mauri FM, Forti S, Eccher C, Mauri FA, Togni R, Palma
PD and Doglioni C (1994) Quantitative growth fraction evaluation with MIB1
and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 102: 171–175
Bartelink H, Borger JH, van Dongen JA and Peterse JL (1988) The impact of tumor
size and histology on local control after breast-conserving therapy. Radiother
Oncol 11: 297–303
MIB1 and invasive ductal breast carcinoma 177
British Journal of Cancer (1999) 79(1), 172–178 © Cancer Research Campaign 1999178 H Imamura et al
British Journal of Cancer (1999) 79(1), 172–178 © Cancer Research Campaign 1999
Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J and Gerdes J
(1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen
(MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-
fixed paraffin sections. J Pathol 168: 357–363
Collan YUI, Kuopio T, Baak JPA, Becker R, Bogomoletz WV, Deverell M, van
Diest P, van Galen C, Gilchrist K, Javed A, Kosma V-M, Kujari H, Luzi P,
Mariuzzi GM, Matze E, Montironi R, Scarpelli M, Sierra D, Sisti S, Toikkanen
S, Tosi P, Whimster WF and Wisse E (1996) Standardized mitotic counts in
breast cancer evaluation of the method. Pathol Res Pract 192: 931–941
Dettmer P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath
W, Schmitt M, Graeff H and Höfler H (1997) Prognostic impact of
proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative
breast cancer. Br J Cancer 75: 1525–1533
Elston CW and Ellis IO (1991) Pathological prognostic factors in breast cancer. I.
The value of histological grade in breast cancer: experience from a large study
with long-term follow-up. Histopathology 19: 403–410
Gerdes J, Schwab U, Lemke H and Stein H (1983) Production of a mouse
monoclonal antibody reactive with a human nuclear antigen associated with
cell proliferation. Int J Cancer 31: 13–20
Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM and Mansel RE (1997) The
clinical behavior of breast carcinoma is probably determined at the preinvasive
stage (ductal carcinoma in situ). Cancer 80: 1740–1745
Haerslev T, Jacobsen GK and Zedeler K (1996) Correlation of growth fraction by
Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry
with histopathological parameters and prognosis in primary breast carcinomas.
Breast Cancer Res Treat 37: 101–113
Hall PA and Levison DA (1990) Review: assessment of cell proliferation in
histological material. J Clin Pathol 43: 184–192
Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ and
Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification.
Semin Diagn Pathol 11: 167–180
Imamura H, Haga S, Shimizu T, Watanabe O, Kajiwara T and Aiba M (1997) MIB1-
determined proliferative activity in intraductal components and prognosis of
invasive ductal breast carcinoma. Jpn J Cancer Res 88: 1017–1023
Kamel OW, Franklin WA, Ringus JC and Meyer JS (1989) Thymidine labeling index
and Ki-67 growth fraction in lesions of the breast. Am J Pathol 134: 107–113
Keshgegian AA and Cnaan A (1995) Proliferation markers in breast carcinoma:
mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67
and MIB-1. Am J Clin Pathol 104: 42–49
Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, Bressac C, Roth
J and Spitalier J-M (1990) Risk factors for breast recurrence in premenopausal
and postmenopausal patients with ductal cancers treated by conservation
therapy. Cancer 65: 1867–1878
Linden MD, Torres FX, Kubus J and Zarbo RJ (1992) Clinical application of
morphologic and immunocytochemical assessments of cell proliferation. Am J
Clin Pathol (Suppl.) 97: 4–13
Lloveras B, Edgerton S and Thor AD (1991) Evaluation of in vitro
bromodeoxyuridine labeling of breast carcinomas with the use of a commercial
kit. Am J Clin Pathol 95: 41–47
McGurrin JF, Doria MI, Dawson PJ, Karrison T, Stein HO and Franklin WA (1987)
Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of
breast. Cancer 59: 1744–1750
Meyer JS (1986) Cell kinetics of histologic variants of in situ breast carcinoma.
Breast Cancer Res Treat 7: 171–180
Meyer JS, Prey MU, Babcock DS and McDivitt RW (1986) Breast carcinoma cell
kinetics, morphology, stage, and host characteristics. Lab Invest 54: 41–51
Mourad WA, Setrakian S, Hales ML, Abdulla M and Trucco G (1994) The
argyrophilic nucleolar organizer regions in ductal carcinoma in situ of the
breast. Cancer 74: 1739–1745
Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V-M and Syrjänen K
(1996) The important prognostic value of Ki-67 expression as determined by
image analysis in breast cancer. J Cancer Res Clin Oncol 122: 687–692
Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson
JR, Blamey RW and Ellis IO (1995) Assessment of the new proliferation
marker MIB1 in breast carcinoma using image analysis: associations with other
prognostic factors and survival. Br J Cancer 71: 146–149
Raymond WA and Leong AS-Y (1989) Nucleolar organizer regions relate to growth
fractions in human breast carcinoma. Hum Pathol 20: 741–746
Silvestrini R, Daidone MG, Luisi A, Mastore M, Leutner M and Sarvadori B (1997)
Cell proliferation in 3,800 node-negative breast cancers: consistency over time
of biological and clinical information provided by 3H-thymidine labelling
index. Int J Cancer 74: 122–127
Weidner N, Moore DH, Ljung B-M, Waldman FM, Goodson WH, Mayall B, Chew
K and Smith HS (1993) Correlation of bromodeoxyuridine (BRDU) labeling of
breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg
Pathol 17: 987–994
Weidner N, Moore DH and Vartanian R (1994) Correlation of Ki-67 antigen
expression with mitotic figure index and tumor grade in breast carcinomas
using the novel ‘paraffin’-reactive MIB1 antibody. Hum Pathol 25: 337–342
Woosley JT (1991) Measuring cell proliferation. Arch Pathol Lab Med 115: 555–557